Predictive value of vascular endothelial growth factor polymorphisms for maintenance bevacizumab efficacy in metastatic colorectal cancer: an ancillary study of the PRODIGE 9 phase III trial.
Fiche publication
Date publication
décembre 2022
Journal
Therapeutic advances in medical oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BOUCHE Olivier, Pr GHIRINGHELLI François
Tous les auteurs :
de Rauglaudre B, Sibertin-Blanc C, Fabre A, Le Malicot K, Bennouna J, Ghiringhelli F, Taïeb J, Boige V, Bouché O, Chatellier T, Faroux R, François E, Jacquot S, Genet D, Mulot C, Olschwang S, Seitz JF, Aparicio T, Dahan L
Lien Pubmed
Résumé
Several studies have reported the impact of single nucleotide polymorphisms (SNPs) in vascular endothelial growth factor () pathway genes on the efficacy of bevacizumab in metastatic colorectal cancer (mCRC), but results are still inconsistent. The PRODIGE 9 phase III study compared bevacizumab maintenance observation alone after induction chemotherapy with FOLFIRI plus bevacizumab.
Mots clés
VEGF, angiogenesis, metastatic colorectal cancer, prognostic biomarker, single nucleotide polymorphism
Référence
Ther Adv Med Oncol. 2022 12 26;14:17588359221141307